TLI Bedrock

TLI Bedrock is a multi-strategy investment firm and venture studio that focuses on the formation and development of innovative biotechnology companies. The firm is particularly known for its role in launching Bedrock Therapeutics, a company dedicated to advancing RNA-based medicines and gene therapies. TLI Bedrock integrates deep scientific expertise with strategic capital to address unmet medical needs across various therapeutic areas, including rare genetic diseases like Stargardt disease and Usher syndrome. Its approach involves hands-on management and a focus on platform technologies that can yield multiple drug candidates. Headquartered in New York, the firm operates at the intersection of finance and scientific innovation to bring novel treatments to market.